

# Sergey Golitsyn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2353275/publications.pdf>

Version: 2024-02-01

39  
papers

15,258  
citations

759055

12  
h-index

182361

51  
g-index

64  
all docs

64  
docs citations

64  
times ranked

9915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology, 2021, 17, 193-199.	0.3	15
2	2020 Clinical practice guidelines for Supraventricular tachycardia in adults. Russian Journal of Cardiology, 2021, 26, 4484.	0.4	8
3	Soluble suppression of tumorigenesis-2 (sST2), a new potential biomarker of response to cardiac resynchronization therapy and cardiac contractility modulation in patients with chronic heart failure. Al'manah KliniĀeskoj Mediciny, 2021, 49, 99-112.	0.2	1
4	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
5	Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation. Terapevticheskii Arkhiv, 2021, 93, 1052-1057.	0.2	2
6	Clinical experience of new antiarrhythmic drug refralon for pharmacological cardioversion in patients with atrial fibrillation after pulmonary vein cryoablation. Journal of Arrhythmology, 2021, 28, 55-62.	0.1	0
7	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety. Rational Pharmacotherapy in Cardiology, 2021, 17, 668-673.	0.3	7
8	Paroxysmal supraventricular tachycardia in patient with dilated cardiomyopathy and concomitant cardiac conduction defects: a case report and discussion. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2368.	0.4	1
9	LOCALIZATION OF THE LEFT VENTRICULAR MYOCARDIAL SCARRING AND ITS ELECTRICAL ACTIVATION IN PATIENTS WITH HEART FAILURE AND DIFFERENT RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY. Journal of Arrhythmology, 2020, 26, 5-14.	0.1	2
10	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
11	Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety. Rational Pharmacotherapy in Cardiology, 2019, 14, 826-830.	0.3	10
12	The effectiveness of cardiac resynchronization therapy in patients with chronic heart failure of various origin depending on the structural myocardial injury in cardiac magnetic resonance imaging. Russian Journal of Cardiology, 2019, , 22-32.	0.4	4
13	The value of cardiovascular magnetic resonance in myocarditis with different clinical presentation. Terapevticheskii Arkhiv, 2019, 91, 28-36.	0.2	4
14	Recent advances in diagnosis and management of atrial fibrillation. Terapevticheskii Arkhiv, 2019, 91, 11-18.	0.2	7
15	Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology, 2018, 14, 664-669.	0.3	20
16	RESULTS OF NON-INVASIVE ACTIVATION MAPPING OF THE HEART IN â€œIDIOPATHICâ€• VENTRICULAR ARRHYTHMIAS IN COMPARISON WITH STRUCTURAL CHARACTERISTICS OF MYOCARDIUM BY MAGNETIC RESONANCE IMAGING. Russian Journal of Cardiology, 2018, , 32-40.	0.4	1
17	Role of electrocardiographic and echocardiographic types of left bundle branch block in prediction of response to cardiac resynchronization therapy. Terapevticheskii Arkhiv, 2018, 90, 76-83.	0.2	6
18	The Changing Landscape for Stroke Prevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	1.2	244

#	ARTICLE	IF	CITATIONS
19	Solid-phase fragment condensation for synthesis of peptides from the immunodominant sequence of $\hat{\text{I}}^21$ -adrenoreceptor. Russian Journal of Bioorganic Chemistry, 2017, 43, 351-358.	0.3	1
20	Pitfalls in rate and rhythm control: Severe concomitant orthostatic hypotension unmasks after conversion to sinus rhythm. Cor Et Vasa, 2017, 59, e450-e453.	0.1	0
21	RESULTS OF CONTINUOUS POSITIVE UPPER AIRWAY PRESSURE TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION AND OBSTRUCTIVE SLEEP APNEA. Russian Journal of Cardiology, 2017, , 111-116.	0.4	5
22	COMPARISON RESULTS OF THE INTRACARDIAC ELECTROPHYSIOLOGICAL STUDY IN PATIENTS WITH TYPICAL ATRIAL FLUTTER AND FIBRILLATION. Russian Journal of Cardiology, 2017, , 125-131.	0.4	1
23	Changes in the receptor activity of $\hat{\text{I}}^22$ -adrenoreceptors of human T-lymphocytes under the effect of $\hat{\text{I}}^22$ -agonists. Molecular Biology, 2016, 50, 880-886.	0.4	1
24	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology, 2015, 11, 577-581.	0.3	10
25	Rare Cause of Wide QRS Tachycardia. Case Reports in Cardiology, 2015, 2015, 1-6.	0.1	0
26	Electrical storm due to myocarditis in post-infarct patient: When two diseases meet. Cor Et Vasa, 2015, 57, e347-e353.	0.1	1
27	COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm, 2015, 12, 1105-1112.	0.3	22
28	Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter. Journal of Cardiovascular Pharmacology, 2014, 64, 247-255.	0.8	8
29	Relationship of Focal Fibrosis According to Magnetic Resonance Tomography, Autoantibodies to Cardiac Membrane Receptors and Ventricular Arrhythmias in Patients With Dilated Cardiomyopathy. Kardiologiya, 2014, 12_2014, 29-36.	0.3	3
30	Synthetic conformational antigen which simulates the extracellular part of the M2-muscarinic receptor: interaction with blood sera of patients suffering from idiopathic arrhythmias. Russian Journal of Bioorganic Chemistry, 2013, 39, 252-258.	0.3	0
31	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	13.9	4,215
32	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	1.6	195
33	A case of arrhythmia due to myocarditis treated by antiviral therapy: new diagnostic approaches using peripheral biomarkers. European Heart Journal, 2013, 34, 17-17.	1.0	3
34	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 806-817.	13.9	2,207
35	Dronedaronone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547
36	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537

#	ARTICLE	IF	CITATIONS
37	Systems Biology and grid technologies: Challenges for understanding complex cell signaling networks. <i>Future Generation Computer Systems</i> , 2007, 23, 428-434.	4.9	5
38	Atrial Appendage Transcriptional Profile in Patients with Atrial Fibrillation with Structural Heart Diseases. <i>Annals of the New York Academy of Sciences</i> , 2006, 1091, 205-217.	1.8	13
39	Paroxysmal supraventricular tachycardia in a patient with dilated cardiomyopathy and concomitant cardiac conduction disorders. Clinical case and discussion of the problem. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 0, 19, .	0.4	0